EA201992594A1 - Комбинированные терапии для лечения рака - Google Patents

Комбинированные терапии для лечения рака

Info

Publication number
EA201992594A1
EA201992594A1 EA201992594A EA201992594A EA201992594A1 EA 201992594 A1 EA201992594 A1 EA 201992594A1 EA 201992594 A EA201992594 A EA 201992594A EA 201992594 A EA201992594 A EA 201992594A EA 201992594 A1 EA201992594 A1 EA 201992594A1
Authority
EA
Eurasian Patent Office
Prior art keywords
cancer
treatment
combined therapies
agent
signaling pathway
Prior art date
Application number
EA201992594A
Other languages
English (en)
Inventor
Дмитри Бобилев
Брюс Дезьюб
Пэн Сунь
Эндрю Р. Фергюсон
Original Assignee
Тесаро, Инк.
Мерк Шарп и Доум Б.В.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Тесаро, Инк., Мерк Шарп и Доум Б.В. filed Critical Тесаро, Инк.
Priority claimed from PCT/US2018/031876 external-priority patent/WO2018208968A1/en
Publication of EA201992594A1 publication Critical patent/EA201992594A1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biophysics (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oncology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

В настоящем изобретении предлагаются способы лечения рецидивирующего рака (рецидивирующих раков) путем применения комбинированной терапии, включающей средство, которое ингибирует активацию сигнального пути рецептора программируемой гибели клеток типа 1 (PD-1), и средство, которое ингибирует активацию сигнального пути поли[ADP-рибоза]полимеразы (PARP).
EA201992594A 2018-03-26 2018-05-09 Комбинированные терапии для лечения рака EA201992594A1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862648327P 2018-03-26 2018-03-26
PCT/US2018/031876 WO2018208968A1 (en) 2017-05-09 2018-05-09 Combination therapies for treating cancer

Publications (1)

Publication Number Publication Date
EA201992594A1 true EA201992594A1 (ru) 2020-03-20

Family

ID=69942862

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201992594A EA201992594A1 (ru) 2018-03-26 2018-05-09 Комбинированные терапии для лечения рака

Country Status (1)

Country Link
EA (1) EA201992594A1 (ru)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11622961B2 (en) 2017-05-18 2023-04-11 Tesaro, Inc. Combination therapies for treating cancer
US11661453B2 (en) 2017-09-30 2023-05-30 Tesaro, Inc. Combination therapies for treating cancer with niraparib and PD-1 inhibitors
US11801240B2 (en) 2017-10-06 2023-10-31 Tesaro, Inc. Combination therapies and uses thereof

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11622961B2 (en) 2017-05-18 2023-04-11 Tesaro, Inc. Combination therapies for treating cancer
US11661453B2 (en) 2017-09-30 2023-05-30 Tesaro, Inc. Combination therapies for treating cancer with niraparib and PD-1 inhibitors
US11801240B2 (en) 2017-10-06 2023-10-31 Tesaro, Inc. Combination therapies and uses thereof

Similar Documents

Publication Publication Date Title
MX2019013755A (es) Terapias de combinación para el tratamiento del cáncer.
MX2019013373A (es) Terapias de combinación para tratar cáncer.
MY193229A (en) Pd-l1 antagonist combination treatments
EA201792191A1 (ru) Комбинированная терапия fgfr/pd-1 для лечения злокачественной опухоли
EA201992594A1 (ru) Комбинированные терапии для лечения рака
BR112018003985A2 (pt) macrociclos peptidomiméticos e usos dos mesmos
MX2017015308A (es) Combinacion de un antagonista de pd-1 y un oligonucleotido tipo cpg-c para tratar cancer.
MX2022001075A (es) Compuestos para usarse en el tratamiento de cancer de mama que expresa el receptor de androgenos (ar+).
MX2017011206A (es) Combinacion de un antagonista con muerte programada 1 (pd-1) y eribulina para el tratamiento de cancer.
MX2019008158A (es) Terapia de combinacion para el tratamiento del cancer.
MX2019011858A (es) Metodos para tratar el cancer con anticuerpos dirigidos a ps con agentes inmunooncologicos.
PH12019502259A1 (en) Glucocorticoid receptor modulators to treat cervical cancer
BR112017028530A2 (pt) terapia combinada para tratamento de cânceres hematológicos e tumores sólidos
EA201990567A1 (ru) Комбинированная терапия с ингибиторами глутаминазы
MX2020008906A (es) Compuestos con actividad inductora de ferroptosis y métodos de uso de estos.
MX2019012464A (es) Terapia combinada con un conjugado de anticuerpo y farmaco anti-axl.
EA202191556A1 (ru) Комбинированная терапия радиоиммуноконъюгатами и ингибиторами контрольных точек
AR116121A1 (es) Métodos de tratamiento del cáncer
EA201892284A1 (ru) Комбинация антитела против cd20, селективного ингибитора pi3-киназы-дельта и ингибитора btk для лечения b-клеточных пролиферативных расстройств
BR112022011998A2 (pt) Usos de anticorpos anti-tgfss e inibidores de checkpoint para o tratamento de doenças proliferativas
CR20220353A (es) Compuestos y métodos para la degradación dirigida del receptor de andrógenos
ZA201907225B (en) Treatment of her2 positive cancers
MX2019003994A (es) Combinacion de un antagonista de proteina de muerte programada-1 (pd-1) y eribulina para el tratamiento de cancer urotelial.
MX2019010149A (es) Inhibicion del smarca2 para el tratamiento del cancer.
MX2020008408A (es) Imagenologia y terapia dirigidas por la granzima b.